EU – Russia Symposium on S&T Co-operation in Biotechnology Moscow, 14 – 15 March 2005 EU Strategies for Life Sciences and Biotechnology Research Dr. Christian Patermann European Commission DG Research

Overview - EU Research, - Life Sciences and Biotechnology Strategy - Developments towards FP7 (2006-2013)

The Lisbon objective The strategic objective set at Lisbon in March 2000 for the following decade, by the heads of government of the European Union, to become: the most competitive and dynamic knowledge-based economy in the world capable of sustainable economic growth with more and better jobs and greater social cohesion.

Life Sciences and Biotechnology- A Strategy and Action Plan for Europe COM(2002)27 -23 January 2002 In January of this year, the EC has produced, in response to the request by the Barcelona Summit, a Communication entitled Life Sciences and Biotechnology: a Strategy for Europe. This Communication proposes an integrated strategy to develop and govern life sciences and biotechnology in Europe, in a sustainable and responsible manner. This Communication has been welcomed at the Stockholm EU Summit in March this year, has received the support of the EP and is going to be submitted to formal conclusion by the Council of EU Ministers in the coming week. How has this strategy been formulated and what are its caracteristsics?

THE POLITICAL DRIVE Lisbon Summit - March 2000 Life Science and Biotechnology A Strategy for Europe THE POLITICAL DRIVE Lisbon Summit - March 2000 Sets a strategic goal for Europe to become the most competitive and dynamic knowledge-based economy in the world Stockholm Summit - March 2001 Highlights the importance of research, entrepreneurship... Identifies biotechnology as a frontier technology … and requests the Commission, together with the Council, to examine measures required to utilise the full potential of biotechnology and strengthen the European biotechnology sector's competitiveness During the past few years, life sciences and biotechnologies have not only been at the leading edge of scientific and technological progress - generating a huge wealth of new knowledge. They have also reached the very heart of European policy making. At the Lisbon Summit in 2000, the EU Heads of State acknowledged life sciences and biotechnology as the “next wave of the knowledge-based economy”. They also set as an objective for Europe to become “the most competitive and dynamic knowledge-based economy in the world capable of sustainable economic growth with more and better jobs and greater social cohesion”. (To reach this objective, a political agreement was reached at the Barcelona Summit in 2002, to increase spending on R&D innovation in the Union to 3% of GDP by 2010).

KEY QUESTIONS Life Science and Biotechnology A Strategy for Europe How can Europe best attract the human, industrial and financial resources to develop and apply these technologies to meet society’s needs and increase its competitiveness? How can Europe deliver effective, credible and responsible policies, which deliver the confidence and support of its citizens? How can Europe best respond to the global challenges, develop its domestic policies with a clear international perspective and act internationally to pursue its interests? The strategy addresses the following three broad questions: The European Parliament and the Heads of State and Government have expressed strong support to the strategy and its 30-point action plan, recognising the potential applications of biotechnology in healthcare, agriculture, food production and environmental protection.

Implementation and COHERENCE Life Science and Biotechnology A Strategy for Europe ACTION PLAN EC + EP + COUNCIL + MEMBER STATES + REGIONS + PRIVATE SECTOR + ACADEMIA + PROFESSIONAL ASSOCIATIONS + CIVIL SOCIETY + EIB + EFSA + EMEA + EGE ... Who? HARVESTING the POTENTIAL 1 GOVERNING Life Sciences and Biotechnology 2 How? In order to implement this strategy, an action plan of 30 concrete measures was proposed. Who are the actors supposed to implement this action plan? A whole range of actors are expected to collaborate and contribute to the strategy and action plan: this goes far beyond the EC, EP and Council and includes MS, regions, private sectors, academia, professional associations, civil society, regulatory agencies such as EFSA, EMEA, ethical bodies. How is the structure of the action plan? The action plan is built in 4 blocks of actions: Harvesting the potential of life sciences and biotech Governing life sciences and biotech in a responsible manner Positioning EU in the world and Responding to global challenges Implementation and coherence across policies 4 Implementation and COHERENCE across policies, sectors and actors 3 RESPONDING to GLOBAL challenges

EUROPE in THE WORLD: RESPONDING to GLOBAL CHALLENGES Life Science and Biotechnology Action Plan EUROPE in THE WORLD: RESPONDING to GLOBAL CHALLENGES A European agenda for international collaboration Europe’s responsibilities towards the developing world Finally, in the third block dedicated to the world-wide perspective of LS &B and the contribution of EU in the world, in order to respond to global challenges, an example of actions is the one dedicated to global Health issues

SUCCESS will depend on MOBILISATION OF ALL ACTORS Ethical Bodies Academia Private Sector Regions RESEARCH DEVELOPMENT REGULATION European Investment Bank Civil Society In conclusion, these were few examples to illustrate the complex strategy and action plan to develop and govern life sciences and biotech in EU in the next coming years. The key messge that I would leave to conclude is that this is an INTEGRATED strategy and that success will depend on the mobilisation of a large number of different major actors. Not only EC, EP and Council, but also MS and regions, ethical bodies, financial bodies, the academia, the private sctor and, last but not least, civil society at large. With a unique final goal the benefit for society Parliament Member States Commission DELIVERABLES FOR SOCIETY

“Research and Innovation must be central to the Lisbon Strategy” José Manuel Barroso President of the European Commission 'returning to growth will require considerable investment in knowledge. [...] Only well trained people can ensure high productivity. This requires an unprecedented effort on research, innovation, education and training. A particular effort will be required to involve young people in this investment for knowledge.' 12/01/2005

Developments towards FP7 (2006-2010)

“I propose to concentrate on Knowledge for Growth” Janez Potočnik European Commissioner for Research ‘Let’s focus on what is our main, if not only, comparative advantage : knowledge … Our competitiveness, the basis for economic growth and employment, depends on how good we are at making the knowledge triangle (education – research – innovation) produce economic value by integrating it in favourable framework conditions which mostly require action at the EU level’ 10/12/2004

Developments towards FP7 (2006-2010) Financial Perspectives 2007 – 2013 (Feb). Proposed doubling of EU research budget Role of EU research support: complement, reinforce, and strengthen the impact of national actions (collaboration; the diffusion of knowledge; the creation of “critical masses” of financial and human resources etc.) FP6 introduced range of initiatives to enhance this value added and provide more structured support. Now necessary to go a step further…

Future Orientations Commission’s Communication on Future Research Policy (16 June) to launch political debate ahead of Proposals for FP7 (early 2005) (http://europa.eu.int/comm/research/future/index_en.html) 6 major objectives to increase the impact of EU’s actions 2 new fields of research: space and security COMMUNICATION FROM THE COMMISSION “Science and technology, the key to Europe's future - Guidelines for future European Union policy to support research” 2 new areas for the Union: space and security Helping to implement European space policy In a changing international context, a European space policy is being put into practice.[2] The current instrument is a framework agreement on cooperation between the European Commission and the European Space Agency (ESA). It involves the development of a strong, scientific, technological and industrial base. Placing research at the service of security Security is a major challenge in Europe: the security of individuals, the State, transport and telecommunications networks in the face of organised crime and international terrorism, in particular bioterrorism. Increasing security involves advancing knowledge regarding detection, intelligence, reconnaissance and surveillance, as well as analysis of the causes of conflicts.

Six Major Objectives 6 axes Technology initiatives new Excellence through collaboration Basic research through competition new 6 axes Human resources Coordination of national programmes Research infrastructures

The challenge The new knowledge and techniques will be central in enabling us to: - switch to a more sustainable agriculture; reduce and reverse environmental degradation; strengthen the competitiveness of our economy; increase agricultural productivity; improve the quality of health care; hence meet the needs of a 50% increase of population; without expanding the farmed area. To achieve this will require a public policy context, at all levels – regional, national, European, OECD, global – which is rationally conceived, to stimulate and welcome innovation.

PROCESSING PRODUCTION THE EUROPEAN KNOWLEDGE-BASED BIOECONOMY QUALITY ASSURANCE STRATEGIES TRACEABILITY, CONSUMER SCIENCE SOCIETAL NEEDS STABILITY - BIODEGRADABILITY FUNCTIONALITY (Chirality) Life sciences & biotechnology for sustainable non-food products + processes “Fork to Farm” Food, health and well-being WHITE BIOTECH CLEAN BIOPROCESSES RAW MATERIALS/WASTE ADVANCED FOOD TECHNOLOGIES, FOOD QUALITY DETERMINANTS, NUTRITION PROCESSING GREEN/BLUE BIOTECH OPTIMISED RAW MATERIALS LOW INPUT FARMING - BIODIVERSITY ANIMAL HEALTH - RURAL DEVT. PRODUCTION Sustainable production and management of biological resources from land, forest, and aquatic environments

The Knowledge-Based Bio-Economy (KBBE) The KBBE reacts to: Growing European and global demand for secure, healthy and sufficient food, produced according to ethically acceptable environmental standards and observing animal protection issues Growing demand to utilise renewable biological instead of fossil resources for energy production and production of industrial goods EU enlargement (doubling of employees in agriculture) Growing risk of food-related diseases etc.

The Knowledge-Based Bio-Economy (KBBE) Innovation and knowledge generation in sustainable management of biological resources (micro-organisms, plants, animals) form the basis for: - new, sustainable, eco-efficient and innovative products for agriculture, food, health and related industrial sectors  Green and red biotechnology, and for biomaterials and “clean” production processes  White biotechnology

EUROPEAN KNOWLEDGE – BASED BIO ECONOMY CONSUMER ACCEPTANCE / INDUSTRY VERTICAL PILLAR 2 Fork to farm: Food, health and well-being VERTICAL PILLAR 3 Life sciences and biotechnology for sustainable non-food products and processes PROCESSING TECHNOLOGIES SUPPORT TO POLICIES BASICS / « OMICS » COMMON ACTIONS (INCO, TRAINING, GENDER,ETHICS, ETC) HORIZONTAL PILLAR 1 : SUSTAINABLE BIOLOGICAL RESOURCES EUROPEAN KNOWLEDGE – BASED BIO ECONOMY

Future bio-agri-food research in FP7? Three possible pillars: Sustainable production and management of biological resources from land, forest, aquatic environments Fork to farm: Food, health and well-being Life sciences and biotechnology for sustainable non-food products and processes

The Future Fossil resources ----------------> Product short-term Bio-catalysis Biomass -------------------------> Product medium-term Optimised ------------------------ > Product long-term Biomass

Future health research in FP7? Three possible areas: Biotechnology: Generic tools and technologies for human health (high-throughput research, detection – diagnosis – monitoring, predicting suitability – safety – efficacy of therapies, innovative therapeutic approaches and intervention) Translating research for human health (integrating biological data and processes - large-scale data gathering - systems biology, brain and related diseases, human development and ageing, translational research into: infectious diseases, cancer, CVD, diabetes / obesity, rare diseases, other chronic diseases) Optimising the delivery of health care to European citizens (translating clinical outcome into clinical practice, quality – efficiency – solidarity of health systems, analysing changes in population, enhanced disease prevention and better use of medicines)

Tentative Timetable 2005 Apr Adoption of FP7 proposal by EC Sep EC proposals on Specific Programmes (SP) and Rules for participation (RfP) Nov EP – First reading on FP 2006 Jan Council – Common position on FP and RfP Mar EP – Second reading on FP and RfP Apr EP – Opinion on SP Jun Council + EP – Adoption of FP and RfP Jul Council – Adoption of SP Oct EC – Adoption of WPGs and model contracts Nov EC – Publication of first calls